Application of Pipiserpin protein in mosquito population control
By developing the new Xa inhibitor Pipiserpin protein, mosquito-borne population control preparations were prepared and animals were inoculated to produce antiserum, the existing mosquito-borne control methods were solved due to insufficient mosquito drug resistance, and the inhibition and hatching rate of mosquito ovarian development was achieved. Reduced, providing new methods for preventing and disease control of mosquito media.
Patent Information
- Application Number
- CN202210210079.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-03-03
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-03-03
AI Technical Summary
The existing mosquito-borne control methods have limited effects due to the development of mosquito resistance, and it is urgent to develop new mosquito-borne control methods to deal with the threat of mosquito-borne diseases.
A novel Xa inhibitor Pipiserpin protein was developed to prepare mosquito-vegetable population control preparations through its encoding genes and amino acid sequences, which are used to inoculate animals to produce antiserum to inhibit mosquito ovarian development and reduce hatching, thereby reducing mosquito population size.
The antiserum of Pipiserpin protein can significantly reduce the hatching rate of mosquito eggs and follicle development, providing a potential method for mosquito-borne control and mosquito-borne disease prevention and control.
Smart Images

Figure CN115725594B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the biological field and relates to the application of Pipsierpin protein in controlling mosquito vector populations. Background Art
[0002] Mosquito-borne diseases still plague the world's population, killing millions of people every year, such as malaria, dengue fever, chikungunya, Zika, West Nile fever, Japanese encephalitis and lymphatic filariasis. In recent years, with the development of global warming, globalization and urbanization, the threat of mosquito-borne diseases has gradually increased. One of the main measures to prevent and control mosquito-borne diseases is still mosquito control. However, as the main method of mosquito control, chemical control has been hampered by the development of mosquito resistance, and new mosquito control methods are urgently needed.
[0003] When female mosquitoes develop their ovaries and ovulate, they need to damage the host's skin to find blood vessels to suck blood, and the injured blood vessels will trigger a series of hemostatic processes such as platelet aggregation, blood coagulation and vasoconstriction in the host. Phospholipid-dependent coagulation factor X (FXa) plays a core role in the coagulation cascade. It can work together through different internal and external pathways to activate factor X (FX) to FXa, promoting subsequent thrombin generation and fibrin formation. In addition, FXa can also participate in inflammation and immune regulation by activating protease-activated receptors. At present, there are reports on three physiological inhibitors of FXa: antithrombin, tissue factor pathway inhibitor (TFPI) and Z protein, and some FXa inhibitors have been cloned and expressed from blood-sucking animals such as ticks, black flies, shrike birds, leeches and mosquitoes. In 1995, Stark and James discovered the presence of anticoagulants in Aedes aegypti, which transmits yellow fever virus, and proved that it was a new type of FXa-specific protease inhibitor; in 2012, Calvo et al. reported another FXa inhibitor that also belongs to the serine family of protease inhibitors: Alboserpin from Aedes albopictus, and proved that Alboserpin can have anti-thrombotic activity by binding to heparin and membrane phospholipids.
[0004] Serine protease inhibitors can control the accidental triggering of protein degradation cascades. When the cascade is activated, they can also regulate the propagation and inhibition of related signals. Therefore, serine protease inhibitors occupy a central position in many biological processes. Of the 23 different serine protease inhibitor families, 12 are found in insects, such as the Kunitz, alpha-macroglobulin, Kazal, and serpin families. Arthropod serine proteins have been confirmed to be involved in regulating a variety of biological functions, including reproduction, development, secretion, and immunity. However, their role in mosquito feeding, pathogen transmission, and potential mosquito vector control has rarely been reported. Summary of the invention
[0005] The purpose of the present invention is to provide application of a novel Xa inhibitor, Pipsierpin protein, in controlling mosquito populations.
[0006] The purpose of the present invention can be achieved through the following technical solutions:
[0007] The invention discloses an application of a gene encoding a Xa inhibitor Pipsierpin in the preparation of a mosquito-borne population control agent. The gene encoding the Xa inhibitor Pipsierpin has a nucleotide sequence shown in SEQ ID No.1.
[0008] The invention discloses an application of a Xa inhibitor Pipsierpin protein in the preparation of a mosquito-borne population control preparation. The Xa inhibitor Pipsierpin protein has an amino acid sequence shown in SEQ ID No.2.
[0009] As a preferred embodiment of the present invention, the mosquito-borne population control agent is an antiserum of Pipsierpin protein.
[0010] The invention discloses an application of a Xa inhibitor Pipsierpin protein in controlling mosquito populations. The Xa inhibitor Pipsierpin protein has an amino acid sequence shown in SEQ ID No.2.
[0011] As a preferred embodiment of the present invention, the Xa inhibitor Pipsierpin protein is used to inoculate animals to produce antiserum for mosquito control and mosquito-borne disease prevention and control.
[0012] Beneficial effects:
[0013] The present invention clones and expresses a novel Xa inhibitor, Pipsierpin, whose antiserum can inhibit mosquito ovarian development and reduce hatching rate. Since mosquitoes feed on animal blood, the Pipsierpin protein in the present invention can be used to inoculate animals to produce antiserum for mosquito control and mosquito-borne disease prevention and control. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 Pipiserpin protein expression and purification
[0015] Figure 2 Western blot analysis of Pipiserpin protein antiserum and mosquito protein extracts
[0016] Figure 3 Pipiserpin protein antiserum reduces the hatching rate of mosquito eggs
[0017] Figure 4 Pipiserpin protein antiserum inhibits mosquito follicle development Specific embodiments
[0018] Example 1 Method for obtaining Pipiserpin gene:
[0019] The full-length sequence of Pipiserpin gene was obtained by PCR amplification using the cDNA of Culex pipiens genome as template.
[0020] ① Extract RNA: Mosquito RNA was extracted from 5 female mosquitoes (1-3 days old). The reagent used for RNA extraction was TRIzol reagent (Thermo Fisher Scientific, USA).
[0021] ② Synthesis of cDNA: According to the operating instructions, we used PrimeScript RT reagent kit (Bao-ichi Biotech, Japan) to synthesize cDNA.
[0022] ③PCR amplification: Using mosquito cDNA as a template, Pipsierpin was amplified by PCR.
[0023] PCR primers were designed based on the FX-mediated anticoagulant gene of Culex pipiens quinquefasciatus (EI accession number: XM_001848396.1).
[0024] Pipiserpin upstream primer: 5'-ATGCTTCGTTGCTTGTTA-3',
[0025] Pipiserpin downstream primer: 5'-ACAAGTCACAAAATTTCTAC-3'
[0026] Each PCR reaction contained 1 unit of Pyrobest Taq DNA polymerase (Takara Biotech, Japan), 10 ng cDNA, 0.4 mM FXa upstream and downstream primers, 0.2 mM dNTPs, and related buffers, with a final volume of 50 ul. The amplification environment was 98°C for 30 seconds, 98°C for 10 seconds, 60°C for 30 seconds, 72°C for 40 seconds, and extended for 30 cycles, and extended at 72°C for 10 minutes.
[0027] ④ The amplified PCR fragment was cloned into the pGEM-T Easy vector (Promega Biotechnology, USA), and nucleotide sequencing was performed using vector-specific primers SP6 and T7 (Promega Biotechnology, USA) and cDNA-specific primers, and the sequence was analyzed using the alignment tools BLAST and ClustalOmega (https: / / www.ebi.ac.uk / Tools / msa / clustalo / ) on the website of the National Center for Biotechnology Information (http: / / ncbi.nlm.nih.gov). The nucleotide sequence of the cloned Pipiserpin gene is shown in SEQ ID No. 1, and the accession number in Genbank is JQ936560.1.
[0028] Example 2
[0029] The gene fragment encoding Pipiserpin amplified in claim 1 was expressed in the Escherichia coli strain Rosetta TM 2 (DE3) (Yubo Biotechnology, Germany) through the expression vector pET-32a (Yubo Biotechnology, Germany). At 37°C, 0.5mM IPTG was added to induce protein expression. His6-labeled Pipiserpin was purified by continuous Ni2+NTA-agarose chromatography and fast protein liquid ion exchange chromatography (HisTrap FF crude, General Medical Group, USA) to purify and extract the protein. The protein concentration was determined using a BCA protein assay kit (Pierce Antibody, USA). The protein purity was evaluated by SDS gel stained with Coomassie dye (Coomassie Brilliant Blue; China). The control group was pET-32a expressed in the Escherichia coli strain Rosetta TM 2 (DE3), and the results are shown in Figure 1 .
[0030] Example 3 Preparation of mouse anti-Pipiserpin serum:
[0031] Six-week-old female BALB / c mice were subcutaneously injected with 50-100ug purified Pipiserpin protein and immunized 4 times to produce antibodies against Pipiserpin. At the same time, pET-32a mouse antiserum was set up as a control group. The titer of the antiserum was determined by indirect ELISA. The OD 450nm (OD450) was read using an ELx800 microplate reader (BioTek, UK). When the titer was higher than 1:50000, the final antiserum was collected. The antiserum was identified by Western blot analysis with mosquito protein extracts. Figure 2 .
[0032] Example 4
[0033] Female mosquitoes that did not mate 2 days after eclosion and male mosquitoes that did not mate 3 days after eclosion were placed in the same cage. Female mosquitoes that mated two days later were divided into six groups to further observe the effect of Pipiserpin on female mosquitoes. The six groups were fed with blood mixed with pET-32a antiserum, pre-immune serum, 5ul, 10ul, 15ul and 20ul of Pipiserpin antiserum (prepared in Example 3), and then the egg rafts were taken out 48 hours after ovulation and incubated in a single tube. The number of eggs and larvae was counted under a stereoscope (OLYMPUS SZX2-FOF, 1J13763, Japan), and the hatching rate (HR) of each egg raft was calculated. The embryonic development of the ovarian 72h PBM and the unhatched egg rafts 72 hours after ovulation was observed under a microscope to check the fertilization situation. The hatching rate of each group was calculated at the same time. The results showed that compared with the pre-immune serum group, the hatching rate decreased significantly after taking Pipiserpin. As the concentration of Pipiserpin antiserum increased, the hatching rate also decreased accordingly. The average hatching rate was inversely proportional to the amount of Pipsierpin antiserum, and the number of eggs per mosquito egg was significantly different among the groups. However, there was no significant difference in the hatching rate and the number of eggs per mosquito egg between the blank group, pET-32a antiserum group, and pre-immune serum group ( Figure 3 ). In order to verify whether Pipsierpin plays a role in the development of ovarian primordial follicles, we observed the size of follicles after taking Pipsierpin. The results showed that the growth of the ovaries was significantly inhibited. The follicle size of mosquitoes in the 5ul, 10ul, 15ul, and 20ul Pipsierpin antiserum groups was much smaller than that of mosquitoes in the pre-immunization group at 72hPBM. As the concentration of Pipsierpin antiserum increased, the degree of inhibition of ovarian development was more serious, and the average follicle size was inversely proportional to the amount of Pipsierpin antiserum. There was no significant difference in follicle size between the blank group, PET-32a antiserum group, and pre-immune serum group ( Figure 4 ).
[0034] The above results all indicate that the Xa inhibitor Pipsierpin can be used as a potential target for mosquito control. When Pipsierpin antiserum is added to the blood, it can hinder the development of mosquito ovaries, reduce the hatching rate of offspring, and thus reduce the number of mosquito populations. Since mosquitoes feed on animal blood, Pipsierpin can be used to inoculate animals to produce antiserum for mosquito control and mosquito-borne disease prevention and control. Sequence Listing <110> Nanjing Medical University <120> Application of Pipiserpin protein in mosquito population control <160> 2 <170> SIPOSequenceListing 1.0 <210> 1 <211> 1246 <212> DNA <213> Culex pipiens pallens <400> 1 ctctccaaag caattgccaa aggattacca agcggagttt gcttggaagt tttacaagca 60 gattagtcaa tcgttcgaaa ctaatatcgt tggctcgcca taccacatca gggaagcatt 120 cgcgtgtctt tcaaacgtct cgttgccttc aaacactttg agcaaagagt tccagaaggc 180 aattctgctc cccaggacta acctaattca cactagatac gacctgcaac gggagcgctt 240 tcagtgtcgg gatgagctga gagttgccac gttggccgca ggattgggca caaagcacgt 300 gctagacggc aagttcagat caacgatgga ccattgcagg atgtttcaaa cgagggttgc 360 aactgatcat gcgataaaga tgacgcaaaa gttgaacgga gtgttttgga atgcgtctaa 420 taatgagatg agaaagttct tgagccccac ggatatcgac gttgattggg atttcctcat 480 tataaactct gttatattga gtgctccctg gaagtaccag tttaagccaa gtgatacaac 540 agtgtgccct ttttacgcta gcaaatccaa acaaatttac acagagttta tgcaagttga 600 aggatacttc cggtacggat attttcgca atggaatttg gcagctgttg aagtaccatt 660 ccaggatggt agtccctatt catgtctgtt gatgcattct atcgacggat ctctctctaa 720 tatgatgaag aattacgatc ataataggtt tcgagagatt tatcaaaagt tgaacgaagg 780 taaaacgacc attattgc cgaaaagtat tataagagtg tcacttaaga gtagcaacat 840 actcaaaagc ttgggattga agactccttt tacggagaaa atttggaagg tattcaattc 900 accaaacggg gcttctcttg gagaatttat gcaaaaagtg acgattcagt ttgaaagtgg 960 agttggacaa atagttaaaa acattcctgg tcgagatctt ggcaatcagt ttatcgcaca 1020 cgaacctttt gtcttcaccg ttttgatcg gcaggagctc acgccgatca tcgtggggca 1080 tttgattgag ccaacaaaaa cagaaaagcc caaatcgaat catttgatgt gccaaaatcc 1140 accaaggtgg acgtttaagg gataattctg ctcgatttgg tagccctagt aaagttatct 1200 ttgaaaaaag tatgaagtgg gttattgtag aaatttgtg acttgt 1246 <210> 2 <211> 387 <212> PRT <213> Culex pipiens pallens <400> 2 Ser Pro Lys Gln Leu Pro Lys Asp Tyr Gln Ala Glu Phe Ala Trp Lys 1 5 10 15 Phe Tyr Lys Gln Ile Ser Gln Ser Phe Glu Thr Asn Ile Val Gly Ser 20 25 30 Pro Tyr His Ile Arg Glu Ala Phe Ala Cys Leu Ser Asn Val Ser Leu 35 40 45 Pro Ser Asn Thr Leu Ser Lys Glu Phe Gln Lys Ala Ile Leu Leu Pro 50 55 60 Arg Thr Asn Leu Ile His Thr Arg Tyr Asp Leu Gln Arg Glu Arg Phe 65 70 75 80 Gln Cys Arg Asp Glu Leu Arg Val Ala Thr Leu Ala Ala Gly Leu Gly 85 90 95 Thr Lys His Val Leu Asp Gly Lys Phe Arg Ser Thr Met Asp His Cys 100 105 110 Arg Met Phe Gln Thr Arg Val Ala Thr Asp His Ala Ile Lys Met Thr 115 120 125 Gln Lys Leu Asn Gly Val Phe Trp Asn Ala Ser Asn Asn Glu Met Arg 130 135 140 Lys Phe Leu Ser Pro Thr Asp Ile Asp Val Asp Trp Asp Phe Leu Ile 145 150 155 160 Ile Asn Ser Val Ile Leu Ser Ala Pro Trp Lys Tyr Gln Phe Lys Pro 165 170 175 Ser Asp Thr Thr Val Cys Pro Phe Tyr Ala Ser Lys Ser Lys Gln Ile 180 185 190 Tyr Thr Glu Phe Met Gln Val Glu Gly Tyr Phe Arg Tyr Gly Tyr Phe 195 200 205 Ser Gln Trp Asn Leu Ala Ala Val Glu Val Pro Phe Gln Asp Gly Ser 210 215 220 Pro Tyr Ser Cys Leu Leu Met His Ser Ile Asp Gly Ser Leu Ser Asn 225 230 235 240 Met Met Lys Asn Tyr Asp His Asn Arg Phe Arg Glu Ile Tyr Gln Lys 245 250 255 Leu Asn Glu Gly Lys Thr Thr Ile Ile Met Pro Lys Ser Ile Ile Arg 260 265 270 Val Ser Leu Lys Ser Ser Asn Ile Leu Lys Ser Leu Gly Leu Lys Thr 275 280 285 Pro Phe Thr Glu Lys Ile Trp Lys Val Phe Asn Ser Pro Asn Gly Ala 290 295 300 Ser Leu Gly Glu Phe Met Gln Lys Val Thr Ile Gln Phe Glu Ser Gly 305 310 315 320 Val Gly Gln Ile Val Lys Asn Ile Pro Gly Arg Asp Leu Gly Asn Gln 325 330 335 Phe Ile Ala His Glu Pro Phe Val Phe Thr Val Phe Asp Arg Gln Glu 340 345 350 Leu Thr Pro Ile Ile Val Gly His Leu Ile Glu Pro Thr Lys Thr Glu 355 360 365 Lys Pro Lys Ser Asn His Leu Met Cys Gln Asn Pro Pro Arg Trp Thr 370 375 380 Phe Lys Gly 385
Claims
1. Application of the gene encoding Xa inhibitor Pipsierpin in the preparation of mosquito population control preparations. The nucleotide sequence of the gene encoding Xa inhibitor Pipsierpin is shown in SEQ ID No.
1.
2. Application of Xa inhibitor Pipsierpin protein in the preparation of mosquito population control preparations. The amino acid sequence of Xa inhibitor Pipsierpin protein is shown in SEQ ID No.
2.
3. The use according to claim 2, characterized in that The mosquito-borne population control preparation is an antiserum of Pipsierpin protein.
